β-blockers as fourth-line therapy for hypertension: stay the course

被引：11

作者：

Bangalore, S. ^{[1
]}

Messerli, F. H. ^{[2
,3
]}

机构：

[1] Brigham & Womens Hosp, Boston, MA 02115 USA

[2] St Lukes Roosevelt Hosp, New York, NY 10025 USA

[3] Columbia Univ, New York, NY USA

来源：

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 2008年 / 62卷 / 11期

关键词：

D O I：

10.1111/j.1742-1241.2008.01916.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the provocative article published in a recent issue ( 1), Henry Krum argues that beta-blockers should remain as the first-line therapy in the management of hypertension. Before we go about reversing any of the national and international guidelines stance on beta-blocker for hypertension, it is essential to scrutinise closely the evidence suggested by Krum for such a change. The arguments listed include evidence of harm only from older generation beta-blockers, possible beneficial effect in the young and in patients with comorbidities.

引用

收藏

页码：1643 / 1646

页数：4

相关论文

共 32 条

[1]

[Anonymous], 1991, JAMA, V265, P3255

[2] Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].

Bakris, GL ;

Fonseca, V ;

Katholi, RE ;

McGill, JB ;

Messerli, FH ;

Phillips, RA ;

Raskin, P ;

Wright, JT ;

Oakes, R ;

Lukas, MA ;

Anderson, KM ;

Bell, DSH .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236

[3] Meta-analysis of 94,492 patients with hypertension treated with beta Blockers to determine the risk of new-onset diabetes Mellitus [J].

Bangalore, Sripal ;

Parkar, Sanobar ;

Grossman, Ehud ;

Messerli, Franz H. .

AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (08) :1254-1262

[4] Cardiovascular protection using beta-blockers - A critical review of the evidence [J].

Bangalore, Sripal ;

Messerli, Franz H. ;

Kostis, John B. ;

Pepine, Carl J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :563-572

[5]

Berenson Alex, 2005, NY TIMES 1114

[6] Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial [J].

Black, HR ;

Elliott, WJ ;

Grandits, G ;

Grambsch, P ;

Lucente, T ;

White, WB ;

Neaton, JD ;

Grimm, RH ;

Hansson, L ;

Lacourcière, Y ;

Muller, J ;

Sleight, P ;

Weber, MA ;

Williams, G ;

Wittes, J ;

Zanchetti, A ;

Anders, RJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16) :2073-2082

[7] How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis [J].

Bradley, Hazel A. ;

Wiysonge, Charles Shey ;

Volmink, Jimmy A. ;

Mayosi, Bongani M. ;

Opie, Lionel H. .

JOURNAL OF HYPERTENSION, 2006, 24 (11) :2131-2141

[8] Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients [J].

Celik, T ;

Iyisoy, A ;

Kursaklioglu, H ;

Kardesoglu, E ;

Kilic, S ;

Turhan, H ;

Yilmaz, MI ;

Ozcan, O ;

Yaman, H ;

Isik, E ;

Fici, F .

JOURNAL OF HYPERTENSION, 2006, 24 (03) :591-596

[9] Effects of nebivolol on platelet activation in hypertensive patients: A comparative study with metoprolol [J].

Celik, Turgay ;

Yuksel, U. Cagdas ;

Iyisoy, Atila ;

Kursaklioglu, Hurkan ;

Ozcan, Omer ;

Kilic, Selim ;

Ozmen, Namik ;

Isik, Ersoy .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 116 (02) :206-211

[10] BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].

COLLINS, R ;

PETO, R ;

MACMAHON, S ;

HEBERT, P ;

FIEBACH, NH ;

EBERLEIN, KA ;

GODWIN, J ;

QIZILBASH, N ;

TAYLOR, JO ;

HENNEKENS, CH .

LANCET, 1990, 335 (8693) :827-838

← 1 2 3 4 →